US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Aptar Pharma
Aptar Pharma Launches Premia™ Precision, a New Quality Standard for Demanding Injectable Therapies
October 05, 2026
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Expands Preservative Free Technology Production in Latin America
September 11, 2026
From
Aptar Pharma
Via
Business Wire
Aptar and Aceso Therapeutics Announce Collaboration to Advance Inhaled Antisense Oligonucleotide Therapy for Cystic Fibrosis
September 07, 2026
From
Aptar Pharma
Via
Business Wire
Noble Secures New Patent for AI-Powered Sound Detection in Drug Delivery and Diagnostic Devices
August 12, 2026
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Announces GMP Certification at Nanopharm, Strengthening Its Integrated Pharma Services Offering
July 22, 2026
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Launches Integrated System-Level Framework to Support Injectable Drug Development
July 17, 2026
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Announces New Patent Applications and Preclinical Data Supporting Investigation of Intranasal and Pulmonary GLP-1 Delivery
May 28, 2026
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Announces Progress on Multi-Year U.S. FDA-Funded Research Contract
May 07, 2026
From
Aptar Pharma
Via
Business Wire
Aptar Pharma and COVIRIX Medical Partner to Develop Inhalable Antiviral Treatments
March 12, 2026
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Continues Global Expansion with Opening of New R&D Center in France
September 25, 2025
From
Aptar Pharma
Via
Business Wire
Aptar Pharma’s Unidose System Delivers Enbumyst™, First U.S. FDA-Approved Intranasal Diuretic
September 18, 2025
From
Aptar Pharma
Via
Business Wire
Aptar Pharma and Dianosic Announce Exclusive Partnership to Advance the Active Resorbable Intranasal Scaffold Platform for the Treatment of Chronic Allergic Rhinitis and Chronic Rhinosinusitis
September 05, 2025
From
Aptar Pharma
Via
Business Wire
Aptar’s First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon’s Otrivin® Brand
July 29, 2025
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition
July 15, 2025
From
Aptar Pharma
Via
Business Wire
RDD Europe 2025, Co-Organized by Aptar Pharma and RDD Online, Celebrates 20 Years
February 27, 2025
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform
November 07, 2024
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Acquires Device Technology Assets of SipNose to Further Expand Intranasal Drug Delivery Portfolio
October 09, 2024
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Celebrates North America Capacity Expansion
September 24, 2024
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Enters into Exclusive Agreement with Pulmotree to Develop and Promote Kolibri™ Non-Propellant Liquid Inhaler Platform
September 09, 2024
From
Aptar Pharma
Via
Business Wire
Aptar Pharma Continues Global Expansion with North America Capacity Extension at Congers, New York Site
March 14, 2024
From
Aptar Pharma
Via
Business Wire
